# A Study of Daratumumab

Source: https://onco.cc/trials/nct05438043/  
OnCo record `nct05438043` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Daratumumab, Carfilzomib, Dexamethasone in multiple myeloma, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

A Study of Daratumumab is a phase 3 interventional study registered as NCT05438043 by Janssen Research & Development, LLC, with 213 participants enrolled, started 2022-12-15 and due to reach its primary completion in 2029-01-31. Interventions recorded: Daratumumab, Carfilzomib, Dexamethasone, Lenalidomide, Pomalidomide. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05438043
- Phase: 3
- Setting: A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 213

## Sources

- ClinicalTrials.gov NCT05438043: https://clinicaltrials.gov/study/NCT05438043

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Carfilzomib](https://onco.cc/drugs/carfilzomib/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Pomalidomide](https://onco.cc/drugs/pomalidomide/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct05438043.json